BA.3.2 is a heavily mutated Omicron subvariant first detected in South Africa in 2024 and now confirmed in more than 20 ...

The 2024-2025 mRNA COVID-19 vaccine provided moderate protection against severe outcomes, including hospitalizations and ED visits.

The COVID-19 landscape remains dynamic, with new variants appearing and spreading across the globe. The FDA’s approval of updated mRNA vaccines in August 2024 was an important step to maintain ...

The 2024-2025 COVID-19 and influenza vaccines provided protection against ED/UC, outpatient visits, and hospitalizations. In the 2024-2025 season, the COVID-19 vaccine provided additional ...

Recent data from the Centers for Disease Control shows spikes in norovirus, Covid-19 and RSV across the U.S.—a resurgence that’s potentially unlike the usual annual winter spread of these illnesses, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Although reports on COVID-19 cases and death have ...

A major new study examining the 2023-2024 COVID-19 vaccines shows moderate protection that works best in the first few months but weakens considerably over time. The research, published in JAMA ...

Changes in the vaccine advisory process in the United States have disrupted immunization guidance, which reinforces the need for independent evidence review to inform decisions regarding immunization ...

The COVID-19 pandemic revealed critical gaps in preparedness and response capacities globally. These gaps were evident in the ...